Envoy Medical (COCH), a Minnesota-based hearing health company developing fully implanted hearing solutions, announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of its pivotal clinical trial for the Acclaim\u00ae cochlear implant to the final stage. The decision follows promising three-month data from the first 10 trial participants, marking a major milestone for the company.<\/p>\n\n\n\n
With the FDA\u2019s approval, Envoy can now move forward with full enrollment ahead of schedule. The company expects to complete enrollment by early 2026, shortening its overall development timeline by three to six months. This acceleration is expected to reduce its capital requirements by $10\u201315 million.<\/p>\n\n\n\n
\u201cThe FDA\u2019s approval to expand our pivotal trial is a game-changing milestone,\u201d said Brent Lucas, CEO of Envoy Medical. \u201cOur data demonstrated strong progress, and we\u2019re now on a faster path toward redefining the standard of care in cochlear implants.\u201d<\/p>\n\n\n\n
The first phase of the study involved 10 patients at five U.S. sites, all of whom successfully completed their three-month evaluations with no serious adverse events. The device was tested in a \u201ccochlear implant only\u201d mode\u2014without external hearing aids\u2014and met performance expectations.<\/p>\n\n\n\n
The second and final stage will include 46 additional participants at seven U.S. trial sites. Given strong patient interest, Envoy anticipates rapid enrollment.<\/p>\n\n\n\n
The company sees significant market potential: of the 2.8 million U.S. adults eligible for cochlear implants, fewer than 5% currently receive them. Envoy believes its fully implanted design\u2014eliminating bulky external hardware\u2014can drive broader adoption and help millions regain hearing confidence.<\/p>\n\n\n\n
Shares of Envoy Medical surged following the announcement, reflecting optimism over its accelerated regulatory progress.<\/p>\n\n\n\n